Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 8 peer-reviewed journal articles Updated
Nephrology

Looking Ahead: Kidney Failure and Transplantation

At a Glance

For people with MIDD who develop kidney failure, a transplant may be possible after treatment deeply and steadily suppresses the abnormal bone marrow cells making the protein. Lifelong blood, urine, and kidney monitoring is needed because deposits can recur in the transplant.

For some patients with MIDD, the disease may eventually lead to Kidney Failure (also known as End-Stage Renal Disease, or ESRD), the point where the kidneys can no longer support the body’s needs. While this is a serious transition, it does not mean your journey has ended.

Life on Dialysis

If your kidneys fail, dialysis becomes necessary to filter your blood. While dialysis performs the work of the kidneys, it does not treat the underlying clone in your bone marrow. Therefore, even on dialysis, you may still need treatment for your bone marrow clone to prevent the monoclonal proteins from depositing in other organs, like your heart or liver [1].

The Path to Transplantation

A kidney transplant can offer a significant improvement in quality of life and long-term health. However, for MIDD patients, the criteria for receiving a new kidney are carefully evaluated. The goal is to ensure that the clone is suppressed before a new, healthy kidney is introduced.

  • The Remission Requirement: Many transplant centers strongly prefer a sustained deep response before they will consider a transplant [2]. This often means achieving at least a Very Good Partial Response (VGPR) or a Complete Response (CR) [3][4]. However, listing criteria and the required duration of response vary by transplant center and patient health.
  • The Waiting Period: You may be asked to wait for a period of months or even a year after achieving remission to ensure the clone does not immediately return.

The Risk of Recurrence

The most significant challenge for MIDD patients is recurrence—the disease coming back in the new kidney.

  • Historical Risks: In historical data, the risk of MIDD returning in the new graft was high, occurring in approximately 54% of cases in a pooled analysis [3].
  • The Impact of Treatment: Modern treatments have significantly improved these odds. In a small retrospective study of LCDD, recurrence occurred in roughly 30% of those treated before transplant, compared to nearly 90% of those who were untreated [4]. These figures come from small historical cohorts, so they should not be used as your current individual risk estimate, which requires evaluation by a transplant team familiar with MIDD.
  • Graft Survival: If the disease does return, it can be a leading cause of graft loss [3].

Protecting the New Kidney

After a transplant, you will be monitored by both a Nephrologist and a Hematologist in a coordinated effort.

  1. Monitoring the Clone: You will continue to have regular marker tests (like sFLC for LCDD, or heavy-chain monitoring for HCDD) [5]. The goal is to catch a “hematologic relapse” before it has time to damage the new kidney.
  2. Monitoring the Graft: Your team will watch your creatinine, eGFR, and urine protein levels closely. If the protein in your urine begins to rise or your kidney function drops, a biopsy of the new kidney may be needed to check for recurrence, rejection, or calcineurin toxicity [6][7].
  3. Treatment After Transplant: If the disease does return in the new kidney, starting clone-directed therapy quickly can help protect the graft and extend its life [3][8].

A transplant requires a lifelong partnership with your medical team to keep the new kidney safe from the original monoclonal proteins.

Common questions in this guide

Can someone with MIDD receive a kidney transplant?
Yes. Kidney transplantation may be considered when the bone marrow clone is deeply and steadily suppressed, often reaching a very good partial response or complete response, but each center sets its own criteria and considers overall health.
Why does remission matter before a kidney transplant for MIDD?
MIDD proteins can return and damage the transplanted kidney if the underlying clone is still active. For this reason, many centers want a sustained deep response, and some ask patients to wait months or longer after remission before transplantation.
How likely is MIDD to return in a transplanted kidney?
MIDD can recur in a transplanted kidney, and older studies reported substantial recurrence. Treatment before transplant was associated with less recurrence in small historical studies, but those results do not predict an individual’s current risk; a specialized transplant team must assess it.
What will be monitored after a kidney transplant for MIDD?
Your team may check blood markers of the abnormal protein-producing clone, including serum free light chains for LCDD or heavy-chain markers for HCDD, as well as creatinine, estimated kidney filtration rate, and urine protein. If results worsen, a kidney biopsy may help distinguish recurrence from rejection or medication-related toxicity.
Would dialysis or clone treatment continue if my kidneys fail?
Dialysis filters the blood when the kidneys can no longer do so, but it does not stop the bone marrow clone. People on dialysis may still need clone-directed treatment to reduce the chance of protein deposits damaging organs such as the heart or liver.
How long should remission be stable before kidney transplantation?
There is no single waiting period for everyone. Transplant centers may look for low, stable markers and a sustained deep response, then require months or sometimes a year before transplantation; the exact timing depends on center policy and your health.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on Non-amyloid monoclonal immunoglobulin deposition disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What specific 'depth' of response (CR, VGPR, or MRD negativity) does this transplant center require before I can be listed?
  2. 2.How long must my light chain levels be stable and low before we consider the 'remission' sustained enough for a transplant?
  3. 3.If the disease returns in the new kidney, what is our plan for treatment to protect the graft?
  4. 4.Does my center have experience with MIDD specifically, and what are their outcomes for patients with this condition?
  5. 5.How often will my blood and urine be tested after the transplant to watch for a relapse of the bone marrow clone?

References

References (8)
  1. 1

    Long-term outcomes and renal responses following autologous hematopoietic stem cell transplantation for light chain deposition disease: a retrospective study on behalf of the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.

    Garderet L, Gras L, Koster L, et al.

    Haematologica 2024; (109(8)):2619-2627 doi:10.3324/haematol.2023.284520.

    PMID: 38546696
  2. 2

    Kidney Transplantation in Patients With Monoclonal Gammopathy of Renal Significance.

    Sprangers B, Hegenbart U, Wetzels JFM

    Transplantation 2023; (107(5)):1056-1068 doi:10.1097/TP.0000000000004443.

    PMID: 36584374
  3. 3

    Systematic Review of Kidney Transplant Outcomes in Monoclonal Ig Deposition Disease.

    Heybeli C, Leung N

    Kidney international reports 2026; (11(5)):106372 doi:10.1016/j.ekir.2026.106372.

    PMID: 42011301
  4. 4

    Kidney Transplantation in Patients With Monoclonal Gammopathy of Renal Significance (MGRS)-Associated Lesions: A Case Series.

    Heybeli C, Alexander MP, Bentall AJ, et al.

    American journal of kidney diseases : the official journal of the National Kidney Foundation 2022; (79(2)):202-216 doi:10.1053/j.ajkd.2021.04.015.

    PMID: 34175375
  5. 5

    The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group.

    Leung N, Bridoux F, Batuman V, et al.

    Nature reviews. Nephrology 2019; (15(1)):45-59 doi:10.1038/s41581-018-0077-4.

    PMID: 30510265
  6. 6

    Diagnosis of light‑chain deposition disease after renal transplantation: A case report and literature review.

    Yue J, Xu F, Zhang Y, et al.

    Experimental and therapeutic medicine 2024; (28(3)):339 doi:10.3892/etm.2024.12628.

    PMID: 39006448
  7. 7

    Assessment of renal outcome following therapy in monoclonal immunoglobulin deposition disease: Emphasizing the need for a consensus approach.

    Pianko MJ, Tiutan T, Derkach A, et al.

    American journal of hematology 2023; (98(3)):421-431 doi:10.1002/ajh.26801.

    PMID: 36588413
  8. 8

    The Role of Kidney Transplantation in Monoclonal Ig Deposition Disease.

    Angel-Korman A, Stern L, Angel Y, et al.

    Kidney international reports 2020; (5(4)):485-493 doi:10.1016/j.ekir.2020.01.011.

    PMID: 32274452

This page is for informational purposes only and does not constitute medical advice. Transplant eligibility, remission requirements, and relapse risk in MIDD must be assessed by your nephrologist, hematologist, and transplant team.